InMed Pharmaceuticals (INM) Cash from Investing Activities (2019 - 2024)
InMed Pharmaceuticals (INM) posted quarterly Cash from Investing Activities of -$2.0 for Q1 2024, up 100.0% year-over-year from -$1.0 in Q2 2023, and up 99.99% quarter-over-quarter from -$33606.0 in Q2 2023.
InMed Pharmaceuticals (INM) Cash from Investing Activities (2019 - 2024) Analysis & Trends
InMed Pharmaceuticals' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at -$2.0 for Q1 2024.
- In Q1 2024, Cash from Investing Activities rose 100.0% year-over-year to -$2.0; the TTM figure through Jun 2024 stood at -$161806.0 (up 81.84% YoY), while the FY2024 annual figure was -$9293.0, up 98.6% from the prior year.
- Cash from Investing Activities for Q1 2024 stood at -$2.0, up from -$33606.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $306011.0 in Q4 2021, with the low at -$725457.0 in Q2 2022.
- The 5-year median for Cash from Investing Activities is -$8800.0 (2020), against an average of -$93631.9.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities tumbled 3508.16% in 2023, then jumped 100.0% in 2024.
- InMed Pharmaceuticals' Cash from Investing Activities stood at $918.0 in 2020, then surged by 33234.53% to $306011.0 in 2021, then tumbled by 337.07% to -$725457.0 in 2022, then jumped by 95.37% to -$33606.0 in 2023, then jumped by 99.99% to -$2.0 in 2024.
- Business Quant data shows INM's Cash from Investing Activities at -$2.0 in Q1 2024, -$33606.0 in Q2 2023, and -$128198.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.48 Mn | 1.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -2.00 |
| Mar 31, 2024 | -2.00 |
| Jun 30, 2023 | -33,606.00 |
| Jun 30, 2023 | -33,606.00 |
| Mar 31, 2023 | -128,198.00 |
| Mar 31, 2023 | -128,198.00 |
| Jun 30, 2022 | -725,457.00 |
| Jun 30, 2022 | -725,457.00 |
| Mar 31, 2022 | -3,553.00 |
| Mar 31, 2022 | -3,553.00 |
| Dec 31, 2021 | 306,011.00 |
| Dec 31, 2021 | 306,011.00 |
| Sep 30, 2021 | -250,000.00 |
| Sep 30, 2021 | -250,000.00 |
| Jun 30, 2020 | 918.00 |
| Jun 30, 2020 | 918.00 |
| Mar 31, 2020 | -8,800.00 |
| Mar 31, 2020 | -8,800.00 |
| Dec 31, 2019 | 54,912.00 |
| Dec 31, 2019 | 54,912.00 |